Zobrazeno 1 - 10
of 209
pro vyhledávání: '"Fengzhi, Li"'
Autor:
Xiang Ling, Wenjie Wu, Li Yan, Leslie Curtin, Melanie M. Farrauto, Sandra Sexton, Anmbreen Jamroze, Changjun Yu, Christos Fountzilas, Dean G. Tang, Fengzhi Li
Publikováno v:
Journal of Pharmaceutical Analysis, Vol 14, Iss 11, Pp 101001- (2024)
Externí odkaz:
https://doaj.org/article/bc7a7e34aa5247839ce2ce1bb6832e77
Publikováno v:
Zhongguo linchuang yanjiu, Vol 37, Iss 4, Pp 519-524 (2024)
Objective To explore the appropriate initial dose of remimazolam for painless gastroenteroscopy in elderly patients based on bispectral index (BIS) monitoring. Methods A total of 165 elderly patients who underwent painless gastroenteroscopy at Linyi
Externí odkaz:
https://doaj.org/article/41459e4fec4b47adabe13a9305ed8d40
Autor:
Changjun Yu, Faqing Huang, Kinsley Wang, Mengmeng Liu, Warren A. Chow, Xiang Ling, Fengzhi Li, Jason L. Causey, Xiuzhen Huang, Galen Cook-Wiens, Xiaojiang Cui
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-16 (2023)
Abstract Background The alkaloid camptothecin analog SN38 is a potent antineoplastic agent, but cannot be used directly for clinical application due to its poor water solubility. Currently, the prodrug approach on SN38 has resulted in 3 FDA-approved
Externí odkaz:
https://doaj.org/article/a56e557434774bd7afcb89fbdc19b1c1
Autor:
Fengzhi Li, Xiang Ling, Sayan Chakraborty, Christos Fountzilas, Jianmin Wang, Anmbreen Jamroze, Xiaozhuo Liu, Pawel Kalinski, Dean G. Tang
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-26 (2023)
Abstract There is increasing evidence indicating the significant role of DDX5 (also called p68), acting as a master regulator and a potential biomarker and target, in tumorigenesis, proliferation, metastasis and treatment resistance for cancer therap
Externí odkaz:
https://doaj.org/article/30e67990699f4a9691fd82d5b47de1b1
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-19 (2022)
Abstract Background Epidermal growth factor receptor (EGFR) inhibitors, including cetuximab and panitumumab, are valuable therapeutics for colorectal cancer (CRC), but resistance to these inhibitors is common. The reason for such resistance is not we
Externí odkaz:
https://doaj.org/article/731cde9357de46998ad660a14c68fe5e
Publikováno v:
Energies, Vol 16, Iss 14, p 5263 (2023)
The utilization of the spiral tube heat exchanger (SHE) has become increasingly prevalent in large-scale liquefaction processes. However, the flow pattern and frictional pressure drop of two-phase flow in the spiral tube have been scarcely studied, p
Externí odkaz:
https://doaj.org/article/43d8f56b39444ee1884e26ac164d17ef
Autor:
Fengzhi Li, Ieman A. M. Aljahdali, Renyuan Zhang, Kent L. Nastiuk, John J. Krolewski, Xiang Ling
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-35 (2021)
Abstract The incidence of renal cell carcinoma (RCC) is increasing worldwide with an approximate 20% mortality rate. The challenge in RCC is the therapy-resistance. Cancer resistance to treatment employs multiple mechanisms due to cancer heterogeneit
Externí odkaz:
https://doaj.org/article/1f3bdaee6b6a410b83c62da95ec497be
Publikováno v:
Energies, Vol 16, Iss 11, p 4323 (2023)
Spiral wound tube heat exchanger (SWHE) was confirmed as the core equipment of natural gas liquefaction (LNG). However, there was rare experimental research on large-scale SWHE for LNG, and the theory of heat transfer is not perfect. To investigate t
Externí odkaz:
https://doaj.org/article/ff578c7253414e53bc27285f4502c422
Autor:
Xiang Ling, Wenjie Wu, Ieman A. M. Aljahdali, Jianqun Liao, Sreevidya Santha, Christos Fountzilas, Patrick M. Boland, Fengzhi Li
Publikováno v:
Clinical and Translational Medicine, Vol 12, Iss 5, Pp n/a-n/a (2022)
ABSTRACT Background Pancreatic ductal adenocarcinoma (PDAC), a difficult‐to‐treat cancer, is expected to become the second‐largest cause of cancer‐related deaths by 2030, while colorectal cancer (CRC) is the third most common cancer and the t
Externí odkaz:
https://doaj.org/article/ff7f5691688d42929e672fe9ee33b6d4
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-22 (2019)
Abstract Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery more than two decades ago, the use of survivin as a target for cancer therapeutics has remained a central goal of survivin studies in the cancer field
Externí odkaz:
https://doaj.org/article/74c8cdaf9be84cf2ac90917f712791a5